Location History:
- Claix, FR (2012)
- Grenoble, FR (2023)
Company Filing History:
Years Active: 2012-2024
Title: Odile Filhol-Cochet: Innovator in Tumor Cell Research
Introduction
Odile Filhol-Cochet is a prominent inventor based in Claix, France. She has made significant contributions to the field of medical research, particularly in understanding tumor cell behavior and developing treatment methods for various diseases. With a total of 3 patents, her work has the potential to impact cancer treatment and other health-related issues.
Latest Patents
One of her latest patents is a method for determining the invasive potential of a tumor cell. This invention relates to predicting the invasive potential of tumor cells and the efficiency of treatments. The method utilizes a combination of at least three parameters: the internuclear distance, polarization, and cell-cell connectivity. Another notable patent involves methods and pharmaceutical compositions for treating diseases mediated by the NRP-1/OBR complex signaling pathway. This invention focuses on treating conditions such as cancers, obesity, autoimmune diseases, and infectious diseases by administering an antagonist of the NRP-1/OBR signaling pathway.
Career Highlights
Odile has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and the Commissariat à l'Énergie Atomique et aux Énergies Alternatives. Her experience in these institutions has allowed her to collaborate on groundbreaking research and innovations in the medical field.
Collaborations
Some of her notable coworkers include Claude Cochet and Manuel Thery. Their collaborative efforts have contributed to advancing research in their respective areas of expertise.
Conclusion
Odile Filhol-Cochet's innovative work in tumor cell research and treatment methods showcases her dedication to improving healthcare outcomes. Her patents reflect her commitment to addressing critical medical challenges, making her a significant figure in the field of medical research.